Back to Search
Start Over
PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.
- Source :
-
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Feb 16; Vol. 118 (7). - Publication Year :
- 2021
-
Abstract
- Unlike other cell types, developing B cells undergo multiple rounds of somatic recombination and hypermutation to evolve high-affinity antibodies. Reflecting the high frequency of DNA double-strand breaks, adaptive immune protection by B cells comes with an increased risk of malignant transformation. B lymphoid transcription factors (e.g., IKZF1 and PAX5) serve as metabolic gatekeepers by limiting glucose to levels insufficient to fuel transformation. We here identified aberrant expression of the lactonase PON2 in B cell acute lymphoblastic leukemia (B-ALL) as a mechanism to bypass metabolic gatekeeper functions. Compared to normal pre-B cells, PON2 expression was elevated in patient-derived B-ALL samples and correlated with poor clinical outcomes in pediatric and adult cohorts. Genetic deletion of Pon2 had no measurable impact on normal B cell development. However, in mouse models for BCR-ABL1 and NRAS <superscript>G12D</superscript> -driven B-ALL, deletion of Pon2 compromised proliferation, colony formation, and leukemia initiation in transplant recipient mice. Compromised leukemogenesis resulted from defective glucose uptake and adenosine triphosphate (ATP) production in PON2 -deficient murine and human B-ALL cells. Mechanistically, PON2 enabled glucose uptake by releasing the glucose-transporter GLUT1 from its inhibitor stomatin (STOM) and genetic deletion of STOM largely rescued PON2 deficiency. While not required for glucose transport, the PON2 lactonase moiety hydrolyzes the lactone-prodrug 3OC12 to form a cytotoxic intermediate. Mirroring PON2 expression levels in B-ALL, 3OC12 selectively killed patient-derived B-ALL cells but was well tolerated in transplant recipient mice. Hence, while B-ALL cells critically depend on aberrant PON2 expression to evade metabolic gatekeeper functions, PON2 lactonase activity can be leveraged as synthetic lethality to overcome drug resistance in refractory B-ALL.<br />Competing Interests: The authors declare no competing interest.
- Subjects :
- Adenosine Triphosphate metabolism
Animals
Aryldialkylphosphatase genetics
Carcinogenesis genetics
Cell Line, Tumor
Cells, Cultured
Glucose metabolism
Glucose Transporter Type 1 metabolism
Humans
Membrane Proteins metabolism
Mice
Mice, Inbred C57BL
Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
Protein Binding
Aryldialkylphosphatase metabolism
B-Lymphocytes metabolism
Carcinogenesis metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1091-6490
- Volume :
- 118
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Proceedings of the National Academy of Sciences of the United States of America
- Publication Type :
- Academic Journal
- Accession number :
- 33531346
- Full Text :
- https://doi.org/10.1073/pnas.2016553118